Kildegaard Jonas, Christensen Toke Folke, Hejlesen Ole Kristian
Kildegaard Consult, Frederiksberg, Denmark.
J Diabetes Sci Technol. 2009 Jul 1;3(4):986-91. doi: 10.1177/193229680900300448.
People on insulin therapy are challenged with evaluation of numerous factors affecting the blood glucose in order to select the optimal dose for reaching their glucose target. Following medical recommendations precisely still results in considerable blood glucose unpredictability, often resulting in frustration in the short term due to hypoglycemia and hyperglycemia, and, in the long term, will likely result in complications. The kinetics of insulin do indeed vary significantly and have become an important focus when developing new insulin analogues and delivery systems; however, numerous of other factors impact glycemic variability. These have different dependences and interactions and are therefore difficult to characterize. Some of the factors are highly dependent and influenced by the type of insulin and devices used in therapy. Development of future therapy products is therefore highly focused on how to minimize glycemic variability.
接受胰岛素治疗的患者面临着评估众多影响血糖的因素的挑战，以便选择达到血糖目标的最佳剂量。严格遵循医学建议仍会导致相当大的血糖不可预测性，短期内常因低血糖和高血糖而令人沮丧，从长期来看，可能会导致并发症。胰岛素的动力学确实有很大差异，并且在开发新的胰岛素类似物和给药系统时已成为一个重要的关注点；然而，许多其他因素也会影响血糖变异性。这些因素具有不同的依赖性和相互作用，因此难以描述。其中一些因素高度依赖于治疗中使用的胰岛素类型和设备，并受其影响。因此，未来治疗产品的开发高度关注如何将血糖变异性降至最低。
